
Nov 20, 2026 · 31 min
Tempus bets cancer data can become an AI growth engine
Tempus AI CEO Eric Lefkofsky on Cancer Data and the $1.5B Personalis Acquisition
Tempus is trying to turn diagnostic testing, matched clinical data, and AI tools into a scalable healthcare platform with faster growth and profitability.
- 1Tempus combines cancer sequencing with matched clinical outcomes to serve physicians and pharmaceutical companies.
- 2Its moat rests on hospital connections, multimodal data, clinical workflows, and proprietary AI infrastructure—not data volume alone.
- 3Personalis could expand Tempus into minimal residual disease testing, while larger data deals could accelerate growth beyond diagnostics.
Don't miss
Lefkofsky argues that the Personalis acquisition could open a minimal residual disease market larger than Tempus’s therapy-selection business.
The brief
Eric Lefkofsky presents Tempus as two businesses built on one foundation: sequencing patients for clinical care and licensing matched clinical and molecular data to drug developers.
The company’s claimed moat is not simply its more than 600 petabytes of data, but the difficult network of connections linking over 8,000 hospitals to clinical workflows.
Tempus’s AI tools already target practical oncology tasks, including cancer predictions, patient summaries, prior authorizations, and clinical-trial matching for physicians.
The planned $1.5 billion Personalis acquisition would add blood-based minimal residual disease testing, which Lefkofsky says could eventually exceed therapy-selection testing.
Lefkofsky’s central investor argument is that Tempus has been valued mainly as diagnostics, while its data business may carry technology-like economics and drive greater profitability.
What was said on this episode
16 statements · 14 positive · 2 negative
- Eric Lefkofskyon AI in healthcarePositive0:34
AI should improve physicians from good to great and from great to superhuman.
“we need to make good doctors great doctors and great doctors superhuman doctors”
Listen at 0:34
- Eric Lefkofskyon TempusPositive1:58
Tempus is among the world’s largest cancer-patient sequencing companies.
“We are one of the largest sequencers of patients, particular cancer patients in the world.”
Listen at 1:58
- Eric Lefkofskyon TempusPositive10:49
Tempus has access to data from 50 million U.S. patients.
“we have 50 million patients in the US”
Listen at 10:49
Loading patient clinical data into frontier models benefits patients at scale.
“there's been a clear, significant advantage to patients at scale loading some of their clinical data into these large frontier models”
Listen at 12:05
Current frontier models are not designed for complex hospital cases.
“These models weren't designed to interrogate that level of complexity.”
Listen at 13:00
- Eric Lefkofskyon MRD testingPositive17:58
MRD testing detects blood cancer cells months before imaging detects recurrence.
“We can detect these cancer cells in the blood six months, nine months, a year before the scan would show up.”
Listen at 17:58
- Eric Lefkofskyon Tempus MRD businessPositive19:03
Tempus’s MRD volume may eventually exceed its therapy-selection volume.
“it would not surprise me if Several years down the road, the volume we generate from MRD is greater than the volume we generate from our therapy selection work.”
Listen at 19:03
- Eric Lefkofskyon Oncology phase-two clinical studiesNegative20:39
Oncology phase-two clinical studies have a 60–70% failure rate.
“the failure rate of phase two clinical studies in oncology is still 60 or 70%, meaning far more fail than succeed.”
Listen at 20:39
- Eric Lefkofskyon Tempus data and AI modelingPositive20:55
Tempus data and AI can improve trial prediction, design, controls, and adverse-event detection.
“they can use our data and our AI modeling capabilities, to help them predict the likelihood of success, help them design a more intelligent study, help them build better control groups, help them figure out if there's adverse events that might cause issues”
Listen at 20:55
- Eric Lefkofskyon TempusPositive21:43
Tempus ended the prior year with over $1 billion in undelivered contract value.
“We finished last year with over a billion dollars in total contract value still to be delivered to our clients.”
Listen at 21:43
- Eric Lefkofskyon Business growth trajectoryPositive25:41
Sustained 25% growth for a decade is preferable to brief 40% growth followed by 15%.
“I'd rather have a business grow at 25% for a decade than grow at 40% for a year and then down to 15%.”
Listen at 25:41
Large frontier-model data licenses could materially exceed Tempus’s normal deals.
“these could be just a phase shift higher than our normal deals”
Listen at 26:27
- Eric Lefkofskyon Tempus algorithmic diagnosticsPositive27:25
Tempus’s algorithmic diagnostics will eventually receive U.S. healthcare reimbursement.
“these algorithms that run on top of healthcare data we collect at some point will be reimbursed by the U.S. healthcare system.”
Listen at 27:25
- Eric Lefkofskyon Tempus data businessPositive28:54
Tempus’s data business is worth more than diagnostic investors recognize.
“our data business, if you were a tech investor, you'd be like, oh my God, that data business is worth more.”
Listen at 28:54
- Eric Lefkofskyon Tempus data businessPositive29:44
Tempus’s data business could trade at 20–40 times revenue if separately public.
“if that thing went public, it would probably trade it, you know, 20 or 30 or 40 times revenue.”
Listen at 29:44
- Eric Lefkofskyon Tempus stockPositive29:56
Investors will eventually recognize Tempus’s data business, creating a stock inflection point.
“one day probably will. And then it will be an inflection point for our stock.”
Listen at 29:56
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.